Oxford Covid-19 vaccine trial paused after participant falls ill | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Wednesday
June 07, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
WEDNESDAY, JUNE 07, 2023
Oxford Covid-19 vaccine trial paused after participant falls ill

Coronavirus chronicle

Reuters
09 September, 2020, 07:40 am
Last modified: 09 September, 2020, 10:11 pm

Related News

  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • AstraZeneca Covid drug neutralises Omicron sub-variants in study
  • Short AstraZeneca shelf life complicates Covid vaccine rollout to world's poorest
  • New data finds AstraZeneca booster generates higher antibodies against Omicron

Oxford Covid-19 vaccine trial paused after participant falls ill

A member of the government's Covid-19 vaccine committee said the health ministry would decide which vaccine trial would be held in the country

Reuters
09 September, 2020, 07:40 am
Last modified: 09 September, 2020, 10:11 pm
Researchers and clinicians in the field of vaccines are advising not to rush into releasing a vaccine without proper safety analyses. Photo: Reuters
Researchers and clinicians in the field of vaccines are advising not to rush into releasing a vaccine without proper safety analyses. Photo: Reuters

AstraZeneca Plc has paused a late-stage trial of one of the leading Covid-19 vaccine candidates due to a suspected serious adverse reaction in a study participant, health news website Stat reported on Tuesday. 

It quoted an AstraZeneca spokesperson as saying in a statement that the "standard review process triggered a pause in vaccination to allow review of safety data."

The study is testing a Covid-19 vaccine being developed by AstraZeneca and University of Oxford researchers at various sites, including the UK, where the adverse event was reported.

Recently, Beximco Pharmaceuticals Ltd announced that it would invest with Serum Institute of India (SII) for the development of the Oxford/AstraZeneca vaccine (AZD1222).

However, after the suspension of the vaccine trial, no decision has been made yet.

Dr Shamsul Hoque, a member of the government's Covid-19 vaccine committee and director at the health directorate's Maternal Nutrition and Child Healthcare Programme, told The Business Standard they came to know about the problem of the Oxford vaccine trial on Wednesday. 

US, European Covid-19 vaccine developers pledge to uphold testing rigour

 

e said no decision had been made yet in this regard, and the health ministry would decide which vaccine trial would be held in the country.

Professor Nazrul Islam, noted virologist and a member of the national technical advisory committee on Covid-19, told The Business Standard there would be a thorough investigation into the illness of a person after receiving the Oxford vaccine. "Only then can a decision be made. We have to wait for that."

The nature of the case and when it happened were not detailed, although the participant is expected to recover, according to Stat.

It said the suspension of the trial has impacted other AstraZeneca vaccine trials as well as clinical trials being conducted by other vaccine makers, which are looking for signs of similar reactions.

The AstraZeneca spokesperson's statement said that illnesses would happen by chance in large trials but those must be independently reviewed and carefully checked.

Stat reported that serious adverse reactions vary and can include issues that require hospitalisation, life-threatening illness and death.

AstraZeneca did not immediately respond to a request for comment, it added. 

Nine leading US and European vaccine developers pledged on Tuesday to uphold scientific safety and efficacy standards for their experimental vaccines despite the urgency to contain the coronavirus pandemic.

What happened to the participant of AstraZeneca vaccine

The companies, including AstraZeneca, Pfizer Inc and GlaxoSmithKline, issued what they called a "historic pledge" after a rise in concern that safety standards might slip in the face of political pressure to rush out a vaccine.

The companies said they would "uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines."

The other signatories were Johnson & Johnson, Merck & Co, Moderna Inc, Novavax Inc, Sanofi and BioNTech.

According to the World Health Organisation, there are about 180 vaccines being developed in the world. However, so far, no vaccine has been able to complete the third-stage trial.

Meanwhile, China and Russia have begun applying locally manufactured vaccines to key workers in their countries. These vaccines are listed as being tested by the World Health Organisation.

On August 27, the Bangladesh government gave the go-ahead for human trials of the Covid-19 vaccine developed by Chinese company Sinovac Biotech.

The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and Sinovac will jointly conduct the trial.

Top News / World+Biz

Oxford Covid-19 Vaccine / AstraZeneca

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Prime Minister Sheikh Hasina. TBS Sketch
    External forces won't put BNP in power, they would rather use the party against govt: PM Hasina
  • Amir Hossain Amu.
    None was called for talks over polls: Amu
  • Photo: UNB
    Amu’s remark on dialogue has no importance to BNP: Fakhrul

MOST VIEWED

  • Covid is no longer global health emergency: WHO
    Covid is no longer global health emergency: WHO
  • Federal police officers stand guard near the house of former Brazilian President Jair Bolsonaro, during a search operation at his home, in Brasilia, Brazil, 3 May, 2023. REUTERS/Adriano Machado
    Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • World Health Organization logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration//File Photo
    Covid here to stay but moving out of emergency phase: WHO
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India reports 12,591 new Covid cases today, 20% more than yesterday
  • People queue up outside a quick test centre to take their coronavirus disease (Covid-19) antigen rapid tests, in Singapore September 21, 2021. Photo :Reuters
    Singapore witnesses new Covid wave: ‘Cases are mostly mild’
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India logs 5,676 new Covid cases, active infections cross 37,000-mark

Related News

  • AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • AstraZeneca Covid drug neutralises Omicron sub-variants in study
  • Short AstraZeneca shelf life complicates Covid vaccine rollout to world's poorest
  • New data finds AstraZeneca booster generates higher antibodies against Omicron

Features

Illustration: TBS

Why aspiration mismatch is a bigger challenge than skill mismatch

8h | Pursuit
Akhand Bharat: What's in a map?

Akhand Bharat: What's in a map?

12h | Panorama
Treatment is a byproduct, not the focus: Inside Bangladesh's largest specialised burn institute 

Treatment is a byproduct, not the focus: Inside Bangladesh's largest specialised burn institute 

9h | Panorama
Marcus Ashworth/Columnist

Brics raging against the dollar is an exercise in futility

9h | Panorama

More Videos from TBS

DU students are suffering due to electricity

DU students are suffering due to electricity

6h | TBS Stories
'Lal Biroi' in Gaibandha

'Lal Biroi' in Gaibandha

7h | TBS Stories
Imran fears re-arrest

Imran fears re-arrest

1d | TBS World
Zlatan Ibrahimovic retires from football

Zlatan Ibrahimovic retires from football

1d | TBS SPORTS

Most Read

1
bKash denied permission to pay $4.10 lakh for Argentina football partnership
Banking

bKash denied permission to pay $4.10 lakh for Argentina football partnership

2
Photo: Noor-A-Alam/TBS
Splash

The Night Dhaka did NOT vibe with Anuv Jain

3
Country's first floating solar power plant connected to national grid
Energy

Country's first floating solar power plant connected to national grid

4
Photo: TBS
Environment

Green space in Dhaka North declines 66% in 3 decades: Study

5
Photo: TBS
Energy

2nd unit of Payra power plant to shut down over coal shortage

6
Photo: Md Jahidul Islam
Environment

After Dhaka South, Dhaka North fells trees on Technical intersection

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]